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Adiponectin controls the apoptosis and the expression
of tight junction proteins in brain endothelial cells
through AdipoR1 under beta amyloid toxicity
Juhyun Song1,2, Seong-Min Choi3, Daniel J Whitcomb4 and Byeong C Kim*,3
Alzheimer’s disease (AD) is the most common neurodegenerative disease, characterized by excessive beta amyloid (Aβ)
deposition in brain, leading to blood–brain barrier (BBB) disruption. The mechanisms of BBB disruption in AD are still unclear,
despite considerable research. The adipokine adiponectin is known to regulate various metabolic functions and reduce
inflammation. Though adiponectin receptors have been reported in the brain, its role in the central nervous system has not been
fully characterized. In the present study, we investigate whether adiponectin contributes to the tight junction integrity and cell
death of brain endothelial cells under Aβ-induced toxicity conditions. We measured the expression of adiponectin receptors
(AdipoR1 and AdipoR2) and the alteration of tight junction proteins in in vivo 5xFAD mouse brain. Moreover, we examined the
production of reactive oxygen species (ROS) and the loss of tight junction proteins such as Claudin 5, ZO-1, and inflammatory
signaling in in vitro brain endothelial cells (bEnd.3 cells) under Aβ toxicity. Our results showed that Acrp30 (a globular form of
adiponectin) reduces the expression of proinflammatory cytokines and the expression of RAGE as Aβ transporters into brain.
Moreover, we found that Acrp 30 attenuated the apoptosis and the tight junction disruption through AdipoR1-mediated NF-κB
pathway in Aβ-exposed bEnd.3 cells. Thus, we suggest that adiponectin is an attractive therapeutic target for treating BBB
breakdown in AD brain.
Cell Death and Disease (2017) 8, e3102; doi:10.1038/cddis.2017.491; published online 12 October 2017
Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by toxic plaques that consist of beta amyloid
(Aβ) peptides generated from amyloid precursor protein
(APP).1–3 The excessive accumulation of these plaques in
the brain impairs synaptic function and leads to neuronal
death, ultimately manifesting in memory dysfunction.1,4 Aβ
has been known to trigger a synaptopathy of reactive oxygen
species (ROS) production, neuronal cell death, glia activation,
and tau hyperphosphorylation.5 In addition to directly effecting
neurons, Aβ is also known to be deposited on the walls of
blood vessels and induce inflammation in endothelial cells.6,7
A critical consequence of this is the disruption of the blood–
brain barrier (BBB) integrity8,9 through ROS production and
secretion of pro-inflammatory cytokines.10 BBB comprises
several cells including brain endothelial cells, interconnected
by tight junctions consisting of the junctional adhesion
molecule 1 (JAM-1), zona occludens 1 (ZO-1), occludin, and
claudin.11,12 In AD, BBB is damaged by Aβ accumulation;13,14
its structure is changed by the disruption of tight junction
proteins and the permeability of BBB is elevated during the
progress of disease.15,16 For these reasons, recent research-
ers have focused on understanding the BBB disruption-related
mechanisms under Aβ accumulation in order to uncover
effective solutions for alleviating AD pathology,17–19 though a
decisive target remains to be determined.
Adiponectin is a 244 amino acid polypeptide adipokine
encoded by the ADIPOQ gene.20 It binds to two receptors
(AdipoR1 and AdipoR2),21,22 which exist in the brain aswell as
other organs throughout the body.23,24 Adiponectin is known to
play key roles as an insulin sensitizer and an anti-inflammatory
regulator, in addition to the regulation of glucose metabolism
and fatty acid breakdown.25,26 In the central nervous system,
previous reports suggest that adiponectin modulates memory
function and has a protective effect on neurons and neural
stem cells against stress condition.27,28 One study showed
that serum adiponectin levels were lower in APP transgenic
mice compared with control mice and outlined an association
with inflammation and cognitive dysfunction in AD.29 More-
over, adiponectin reduces the secretion of interleukin-6 (IL-6)
from brain endothelial cells in response to oxidative stress,
modulating BBB function.30 Judging from previous evidences,
adiponectin has the potential to play a cellular protective role in
brain endothelial cells under Aβ-induced oxidative stress and
attenuate the BBB disruption caused by Aβ accumulation in
AD brain.
In the present study, we investigated whether adiponectin
contributes to the apoptosis of brain endothelial cells and the
loss of tight junction under Aβ toxicity condition. Our findings
suggest that adiponectin may protect BBB disruption in the AD
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brain by alleviating the damage of brain endothelial cells
caused by Aβ toxicity.
Results
The expression of adiponectin receptors was reduced in
5xFAD mouse brain. To examine the expression of adipo-
nectin receptors (AdipoR1 and AdipoR2) in 5xFAD mouse
brain, we measured the expression of adiponectin receptors
through western blotting (Figures 1a and b) and immunos-
taining (Figures 1f and g). In 5xFAD mouse brain, the protein
level of AdipoR1 was significantly reduced compared with the
control mouse brain (Con) (Figure 1a). The protein level of
AdipoR2 also showed a slight, albeit non-significant decrease
of protein level in 5xFAD mouse brain in comparison with the
normal mouse brain (Figure 1b). The immunostaining images
showed considerable reduction of AdipoR1 in 5xFAD mouse
brain entorhinal cortex and striatum (Figure 1f). Figure 1g
presents the reduction of AdipoR2 in 5xFAD mouse brain
entorhinal cortex and striatum (Figure 1g). These data
suggest that levels of adiponectin receptors (AdipoR1 and
AdipoR2) are altered in 5xFAD mouse brain (Figures 1a,b,f,
and g). Figure 1h shows the PSD95 (postsynaptic protein95;
considered as neuron) and AdipoR1, AdipoR2 colocalization
in brain (Figure 1h). Based on our results of the colocalization
of PSD95 and AdipoR1 or AdipoR2, we showed the
expression of AdipoR1 and AdipoR2 in neuronal cells.
The increase of NF-κB phosphorylation and the loss of
tight junction protein in 5xFAD mouse brain. To examine
whether AD triggers the inflammatory signaling such as NF-
κB, we assess the alterations of NF-κB phosphorylation
Figure 1 The expression of adiponectin receptors and the activation of NF-κB and the decreased Claudin 5 protein in 5xFAD mouse brain. Western blotting showed the
protein level of AdipoR1 (a) and AdipoR2 (b) in 5xFAD mouse brain. (a) The protein level of AdipoR1 was significantly reduced in 5xFAD mouse brain compared to the control
mouse brain. (b) The protein level of AdipoR2 was slightly reduced in 5xFAD mouse brain compared to the control mouse brain. (c) Western blotting showed the protein level of
p-NF-κB in mouse brain. The protein level of p-NF-κB was significantly increased in 5xFAD mouse brain compared to the control mouse brain. (d) Western blotting showed the
protein level of Claudin 5 in mouse brain. The protein level of Claudin 5 was significantly reduced in 5xFAD mouse brain in comparison with the control mouse brain. (e) The
protein level of CD31 was slightly reduced in 5xFAD mouse brain compared to the control mouse brain. Data are expressed as mean± S.E.M., and each experiment conducted
three repeats per conditions. β-actin was used as control. Differences were considered significant at *Po0.05, **Po0.01. Images showed the expression of AdipoR1 (Green) (f)
and AdipoR2 (Green) (g). 5xFAD mouse showed the less expression of AdipoR1 (f) and AdipoR2 (g). (h) PSD95-positive cells matched with the AdipoR1 and AdipoR2 staining
cell in brain. Con: control normal mouse, 5xFAD: 5xFAD mouse, Scale bar: 50 μm, 4',6-diamidino-2-phenylindole (DAPI): blue, AdipoR1: adiponectin receptor 1 (Green),
AdipoR2: adiponectin receptor 2, p-NF-κB: phosphorylation of NF-kB, PSD95: postsynaptic density protein 95
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(Figure 1c). Also, to check the loss of tight junction proteins
(Figure 1d) that may occur as a result of AD pathology, we
conducted western blotting analysis using Claudin 5 antibody
by extracting the proteins in the 5xFAD mouse brain
(Figures 1c and d). Figure 1e shows the protein level of
CD31 as a vascular marker (Figure 1e). Western blotting data
showed that the activation of NF-κB was markedly increased
in 5xFAD mouse brain in comparison with the control mouse
brain (Figure 1c), suggestive of the activation of NF-κB
pathway in 5xFAD mouse brain (Figure 1c). Also, western
blotting data suggested that Claudin 5 junction protein was
considerably reduced in 5xFAD mouse brain (Figure 1d). This
result demonstrates a relative loss of tight junction protein
Claudin 5 in 5xFAD mouse brain compared with the control
mouse brain (Figure 1d).
The reduction of cell viability and the increase of nitrite
oxide production in Aβ-treated brain endothelial cells. To
investigate the toxicity of Aβ in the brain endothelial cells, we
measured cell viability in bEnd.3 cells by MTT assay
(Figure 2a). The cell viability of brain endothelial cells was
approximately 70% in 10 μM Aβ-treated group and 60% in
20 μM Aβ-treated group (Figure 2a). We treated 20 μM Aβ for
24 h in bEnd.3 cells to study the effect of adiponectin in brain
endothelial cells against Aβ-induced stress condition. When
we treated 20 μM Aβ for 24 h in bEnd.3 cells, we observed a
marked increase of NO production in bEnd.3 cells. Pre-
treatment of Acrp 30 (as an adiponectin globular form)31
10 μg/ml leads to the considerable decrease of NO produc-
tion in bEnd.3 cells, despite Aβ-induced stress condition
(Figure 2b). In addition, we checked the mRNA level of
inducible nitric oxide synthases (iNOS) (as an inducer of NO
production)32 (Figure 2c) and endothelial nitric oxide
synthases (eNOS) by RT-PCR in Aβ-treated bEnd.3 cells
(Figure 2d). The mRNA level of iNOS was increased in Aβ-
treated bEnd.3 cells, and pre-treatment of Acrp 30 reversed
Aβ-induced increase of iNOS mRNA level (Figure 2c). The
mRNA level of eNOS was increased in Aβ-treated bEnd.3
cells, and pre-treatment of Acrp 30 inhibited Aβ-induced
increase of eNOS mRNA level (Figure 2d).
The decrease of tight junction proteins in Aβ-treated
brain endothelial cells. To assess the alterations of tight
junction proteins (Claudin 5 and ZO-1) in Aβ-treated brain
endothelial cells, we conducted quantitative real-time PCR
(Figures 2e and f) and western blotting (Figure 2g). Our
results showed that the mRNA levels of Claudin 5 (Figure 2f)
and ZO-1 (Figure 2e) were decreased in Aβ-treated bEnd.3
cells. The loss of Claudin 5 protein in Aβ-treated bEnd.3 cells
was suppressed by Acrp 30 (10 μg/ml) pre-treatment for 24 h
(Figure 2g). These data suggest that Acrp 30 prevents the
loss of tight junction proteins such as Claudin 5 and ZO-1 in
Aβ-treated bEnd.3 cells (Figures 2e–g).
Acrp30 rescues cell death and inhibits the production of
ROS in bEnd.3 cells under Aβ-induced oxidative stress
condition. To examine whether adiponectin contributes to
the cell death and the production of ROS in Aβ-exposed brain
endothelial cells, we checked the mRNA levels of Bax
(Figure 3a) by quantitative real-time PCR and Bcl2
(Figure 3b) by reverse transcription PCR and the production
of ROS by 2′,7′-dichlorofluorescin diacetate (DCF-DA) assay
in bEnd.3 cells (Figures 3c and d). To confirm the alteration of
cell death by adiponectin, we conducted Hoechst/PI staining
(Figure 3e). We observed that PI-positive cells (death cells)
were reduced by adiponectin treatment under Aβ toxicity
(Figure 3e). Our results indicated that pre-treatment of Acrp
30 reversed Aβ-induced increase of Bax expression, reduc-
tion of Bcl2 expression, and increase of ROS production in
bEnd.3 cells (Figure 3).
The expression of pro-inflammatory cytokines in bEnd.3
cells under Aβ toxicity. To test the expression of inflam-
matory cytokines in Aβ-treated brain endothelial cells, we
checked the mRNA level of IL-6, tumor necrosis factor α
(TNF-α), and monocyte chemoattractant protein-1 (MCP-1) in
bEnd.3 cells by quantitative real-time PCR (Figure 4). We
observed that the expression of IL-6 was slightly increased by
Acrp 30 treatment (Figure 4a). Aβ treatment triggered the
expression of pro-inflammatory cytokine IL-6 (Figure 4a),
TNF-α (Figure 4b), and MCP-1 (Figure 4c) in bEnd.3 cells,
whereas pre-treatment of Acrp 30 reduced the increased
expression of IL-6 (Figure 4a), TNF-α (Figure 4b), and MCP-1
(Figure 4c) in Aβ-exposed bEnd.3 cells.
Aβ leads to the decreased expression of adiponectin
receptor in brain endothelial cells. To confirm the change
of expression of adiponectin receptors in brain endothelial
cells under Aβ toxicity, we checked the expression of
AdipoR1 and AdipoR2 by quantitative real-time PCR
(Figures 5a and b) and immunocytochemistry (Figures 5c
and d). Aβ treatment resulted in the reduction of the mRNA
levels of AdipoR1 and AdipoR2 in bEnd.3 cells (Figures 5a
and b). In Figures 5c and d, immunostaining data shows the
Figure 2 The measurement of nitric oxide production and tight junction protein in bEnd.3 cells under Aβ toxicity. (a)The cell viability in bEnd.3 cells under Aβ-induced toxicity
was assessed by MTTassay. bEnd.3 cells were treated with Aβ at 1, 5, 10, 20 μM for 24 h. The cell viabilities in bEnd.3 cells treated with Aβ 10 μM and 20 μM concentration were
showed below 70% compared to that in control group (only DMSO). The value was calculated as 100% of control (only DMSO). (b) The production of nitrite was measured by
Griess reagent assay. The production of nitrite was increased in Aβ-treated bEnd.3 cells, and pre-treatment of Acrp 30 reversed the Aβ-induced increase of nitrite production.
(c) The mRNA level of iNOS was checked with reverse transcription PCR. The mRNA of iNOS was increased in bEnd.3 cells under Aβ-induced toxicity. (d) The mRNA level of
eNOS was measured with reverse transcription PCR. The mRNA of eNOS was considerably increased in bEnd.3 cells under Aβ-induced toxicity. Pre-treatment of Acrp30
reversed the Aβ-induced increase of iNOSmRNA level in bEnd.3 cells. The mRNA levels of Claudin 5 (f) and ZO-1 (e) were measured with quantitative real-time PCR. The mRNA
levels of Claudin 5 and ZO-1 were reduced in bEnd.3 cells under Aβ-induced toxicity. (e) Pre-treatment of Acrp30 reversed the Aβ-induced decrease of ZO-1 mRNA levels in
bEnd.3 cells. (f) quantitative real-time PCR also revealed that Aβ-induced decrease of Claudin 5 mRNA was reversed by pre-treatment of Acrp30 in bEnd.3 cells. (g) Western
blotting data revealed that Aβ-induced decrease of Claudin 5 protein level was reversed by pre-treatment of Acrp30 in bEnd.3 cells. Differences were considered significant at
*Po0.05, **Po0.001. Data are expressed as mean± S.E.M. GAPDH gene and β-actin were used as control. Con: only DMSO, Acrp30: Acrp 30 10 μg/ml treatment for 24 h,
Aβ: Aβ 20 μM treatment for 24 h, iNOS: inducible nitric oxide synthase
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Figure 3 Adiponectin rescues cell death and inhibits the production of ROS under amyloid beta toxicity. The mRNA levels of Bax (a) were assessed with quantitative real-time
PCR. Also, the mRNA levels of Bcl2 (b) were measured with reverse transcription PCR. Aβ treatment induced increase of Bax mRNA level and decrease of Bcl2 mRNA level in
bEnd.3 cells, and pre-treatment of Acrp30 reversed those changes. (c,d) The production of ROS was measured using DCF-DA reagent. Differences were considered significant
at *Po0.05, **Po0.001. Data are expressed as mean±S.E.M. GAPDH was used as control gene. Aβ-treated bEnd.3 cells showed increase of ROS production, and pre-
treatment of Acrp30 reversed Aβ-induced increase of ROS production in bEnd.3 cells. (e) PI-positive cells (red color) were considered as the dead cells. Scale bar: 100 μm, ROS:
green, Acrp30: Acrp 30 10 μg/ml treatment for 24 h; Aβ: Aβ 20 μM treatment for 24 h, Hoechst: blue color, propidium iodide (PI): red color
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expression of AdipoR1 and AdipoR2 in bEND.3 cells
(Figures 5c and d). Pre-treatment of Acrp 30 reversed Aβ-
induced decrease of AdipoR1, but not of AdipoR2 in bEnd.3
cells (Figures 5a–d).
Acrp30 changes the expression of RAGE and LRP-1 in
bEnd.3 cells under Aβ toxicity. To check the expression of
receptor for advanced-glycation end products (RAGE) and
low-density lipoprotein receptor-related protein 1 (LRP-1) in
brain endothelial cells under Aβ toxicity, we measured the
mRNA levels of RAGE and LRP-1 in Aβ-treated bEnd.3 cells
by quantitative real-time PCR (Figure 6). Aβ triggered the
Figure 4 The expression of pro-inflammatory cytokines in bEND3 cells. The
mRNA levels of IL-6, TNF-α, MCP-1 were detected by quantitative real-time PCR. Aβ
treatment in bEnd.3 cells induced increase of IL-6 (a), TNF- α (b), and MCP-1 (c)
mRNA levels. Pre-treatment of Acrp 30 reversed Aβ-induced increases of each
mRNA levels in bEnd.3 cells (a–c). Data are expressed as mean±S.E.M. GAPDH
was used as control gene. Differences were considered significant at *Po0.05.
Acrp30: Acrp 30 10 μg/ml treatment for 24 h, Aβ: Aβ 20 μM treatment for 24 h Figure 5 The expression of adiponectin receptors in bEnd.3 cells under amyloid
beta toxicity. The mRNA level of AdipoR1 (a) and AdipoR2 (b) were checked by
reverse transcription PCR. The mRNA level of AdipoR1 in bEnd.3 cells was reduced
by Aβ treatment, and pre-treatment of Acrp 30 reversed Aβ-induced decrease of
AdipoR1 in bEnd.3 cells (a,c). The mRNA level of AdipoR2 in bEnd.3 cells was also
reduced by Aβ treatment, whereas pre-treatment of Acrp 30 did not reverse Aβ-
induced decrease of AdipoR2 in bEnd.3 cells (b). Data are expressed as mean± S.
E.M. GAPDH was used as control gene. Differences were considered significant at
*Po0.05, **po0.001. The immunostaining images showed the expression of
AdipoR1 (c) and AdipoR2 (d) in bEnd.3 cells. Scale bar: 100 μm, 4',6-diamidino-2-
phenylindole (DAPI): blue, AdipoR1: green, AdipoR2: green, Acrp30: Acrp 30 10 μg/
ml treatment for 24 h, Aβ: Aβ 20 μM treatment for 24 h. Con: no treatment group, (− )
Ab: IgG control
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increase of RAGE mRNA level in bEnd.3 cells, while Acrp 30
reversed Aβ-induced increase of RAGE mRNA level
(Figure 6a). Aβ triggered the decrease of LRP-1 mRNA level
in bEnd.3 cells, and Acrp 30 reversed Aβ-induced decrease
of LRP-1 mRNA level (Figure 6b).
Acrp 30 protects the tight junction integrity and attenu-
ates the inflammatory responses through AdipoR1. First,
we checked the protein level of Claudin5 in AdipoR1 and
AdipoR2 knockout condition (Figures 7a and b). We used
appropriate non-silencing control siRNA and confirmed the
efficiency of the siRNA knockdown in this study. We
confirmed almost the same protein level of claudin5 in
AdipoR1 and AdipoR2 knockout condition (Figure 7a). Also,
we measured the protein level of Claudin 5 in AdipoR1 and
AdipoR2 knockout cells under Aβ treatment (Figure 7b). We
found that the protein level of Claudin 5 was not largely
changed in AdipoR1 and AdipoR2 knockout condition under
Aβ treatment condition (Figure 7b). To assess whether
adiponectin boosts NF-κB signaling (known as the inflamma-
tory pathway) in Aβ-exposed brain endothelial cells through
AdipoR1, we used siRNA AdipoR1 for knock-down of
AdipoR1 in brain endothelial cells (Figure 7c). We observed
the activation of NF-κB in AdipoR1 knockdown group despite
pre-treatment of Acrp 30 in Aβ-treated bEnd.3 cells
(Figure 7c). In addition, to investigate whether adiponectin
influences tight junction integrity through AdipoR1, we used
siRNA AdipoR1 for knockdown of AdipoR1 in brain endothe-
lial cells (Figure 7d). We observed loss of Claudin 5 by Aβ
toxicity in AdipoR1 knockdown group despite Acrp 30 pre-
treatment (Figure 7d). When we suppress the expression of
AdipoR2 using siRNA AdipoR2, we found a little bit change of
Claudin 5 protein level in brain endothelial cells under Aβ with
Acrp30 treatment condition (Figure 7e). Moreover, we
measured the production of NO by Griess reagent assay
(Figure 7f) and the production of TNF-α by ELISA assay
(Figure 7g) in bEnd.3 cells. Pre-treatment of Acrp 30 did not
reverse Aβ-induced increase of nitric oxide in bEnd.3 cells in
the presence of AdipoR1 knockdown (Figure 7f). Finally, we
examined the expression of Claudin 5 (Figure 8a) and p-NF-
κB (Figure 8b), NF-κB (Figure 8c) in bEnd.3 cells using
immunocytochemisty (Figure 8). Images show that pre-
treatment of Acrp 30 did not reverse the Aβ-induced changes
of Claudin 5 expression and NF-κB activation in bEnd.3 cell in
the presence of AdipoR1 knockdown (Figure 8).
Discussion
AD, a neurodegenerative disorder, is characterized by
abnormal accumulation of Aβ and neurovascular
dysfunction.33 The excessive Aβ deposition in brain endothe-
lial cells aggravates the increase of BBB permeability by
impairing BBB transport systems in the AD brain.14,34
Adiponectin acts by binding with specific receptor AdipoR1
and AdipoR2,21 which exist in various organs including
brain.23,24 Considering that our results showed the AdipoR1
and AdipoR2 detected cells were neuronal cells in brain, we
assume that the adiponectin receptors could be involved in the
excitability of neurons35 and the suppression of neuronal
damage against oxidative stress.36 Also, adiponectin has
been reported that it is present in the cerebrospinal fluid (CSF)
of rodents37,38 and humans,39,40 although the concentration of
it in CSF is less than the concentration of it in plasma and is
controversial whether or not it could cross the BBB.30
Recent studies suggested the protective potential of
adiponectin on BBB breakdown in AD,29,30 but the specific
mechanisms remained to be fully characterized. In the present
study, we found a reduction of AdipoR1 and AdipoR2
expression and the loss of tight junction protein Claudin 5 in
models of AD pathology. These effects were concomitant with
the activation of NF-κB. Taken together, these data suggest
that decreased expression of adiponectin receptors in the AD
brain may be associated with BBB disruption and activation of
the inflammatory response.
Excessive production of ROS can cause severe cell
damage41 and can also increase vascular endothelial perme-
ability and leukocyte adhesions.16 In addition, a large amount
of ROS triggers loss of endothelial cell interactions42 and
affects BBB integrity by disturbing tight junctions.43,44 One
study showed that adiponectin prevents the inflammation of
vascular endothelial cells by reducing the secretion of ROS.45
Considering previous results and our in vitro results, we
suggest that adiponectin may suppress Aβ toxicity-induced
Figure 6 The mRNA levels of RAGE and LRP-1 in bEnd.3 cells under amyloid beta toxicity. The mRNA level of RAGE and LRP-1 were measured by quantitative real-time
PCR. The mRNA level of RAGE (a) was increased and that of LRP-1 (b) was decreased in bEnd.3 cells by Aβ treatment. Pre-treatment of Acrp 30 reversed Aβ-induced changes
of RAGE (a) and LRP-1 (b) mRNA levels in bEnd.3 cells. Data are expressed as mean±S.E.M. GAPDH was used as control gene. Differences were considered significant at
*Po0.05, **Po0.001. Acrp30: Acrp 30 10 μg/ml treatment for 24 h, Aβ: Aβ 20 μM treatment for 24 h
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inflammation and BBB disruption by reducing the production of
ROS in brain endothelial cells.
Previous study demonstrated that Aβ increases the
expression of iNOS gene.46 iNOS produces NO and triggers
the inflammatory response.47 Excessive production of NO in
endothelial cells promotes pro-inflammatory signaling and the
process of APP.48,49 Adiponectin has been known to control
the production of cytokines by regulating the expression of
Figure 7 The change of inflammatory response and the tight junction proteins by inhibiting Adiponectin receptor under amyloid beta toxicity. The protein level of claudin5 was
assessed by western blotting in AdipoR1, AdipoR2 knockout condition (a,b). Panel b shows the protein level of Claudin 5 in AdipoR1, AdipoR2 knockout condition under Aβ
treatment (b). The protein level of p-NF-κB (c) and Claudin 5 (d) were detected by western blotting. (c) The protein level of p-NF-κB was increased in Aβ-treated bEnd.3 cells with
Acrp 30 pre-treatment under AdipoR1 knockdown. (d) The protein level of Claudin 5 was markedly decreased in Aβ-treated bEnd.3 cells with Acrp 30 pre-treatment under
AdipoR1 knockdown. (e)The protein level of Claudin 5 was not decreased in Aβ-treated bEnd.3 cells with Acrp 30 pre-treatment under AdipoR2 knockdown. (f) The production of
NO was checked by Griess reagent assay. The production of NO was increased in Aβ-treated bEnd.3 cells with Acrp 30 pre-treatment under AdipoR1 knockdown. (g) The
production of TNF-α was checked by ELISA assay. The production of TNF-α was increased in Aβ-treated bEnd.3 cells with Acrp 30 pre-treatment under AdipoR1 knockdown.
Data are expressed as mean±S.E.M. β-actin was used as control. Differences were considered significant at *Po0.05, **Po0.001.Acrp30: Acrp 30 10 μg/ml treatment for
24 h, Aβ: Aβ 20 μM treatment for 24 h, siAdipoR1: silencing of AdipoR1
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eNOS.50 In addition, adiponectin inhibits fibroblast migration
through AdipoR1-AMPK-iNOS pathway in inflammatory
condition.51 Based on our results, we infer that adiponectin
contributes to the expression of cytokines and inflammation
signaling by blocking the production of NO against Aβ-induced
toxicity. Several studies demonstrated that adiponectin
reduces the production of IL-6,30 IL-8, vascular endothelial
growth factor and matrix metalloproteinases (MMPs) in
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endothelial cells.52 In addition, the overexpression of adipo-
nectin receptors promotes the anti-inflammatory response in
vascular endothelial cells.53 Also, adiponectin inhibits vascular
endothelial hyperpermeability through cAMP/PKA signaling.54
Regarding our results, we suggest that adiponectin reduces
the expression of pro-inflammatory cytokines including IL-6,
TNF-α and MCP-1 in brain endothelial cells under Aβ-induced
oxidative stress conditions.
In AD, the accumulation of Aβ in endothelial vessel walls
leads to endothelial dysfunction55 and impaired BBB
integrity.56 The loss of tight junction proteins such as occludin,
ZO-1, and Claudin 5 by Aβ aggravates the increase of barrier
permeability and apoptosis of vascular endothelial cells.57,58
The alteration of tight junction and ROS production causes
BBB leakage in AD brains.59 Recent study reported that the
activation of NF-κB byAβ accumulation disrupts the integrity of
BBB by decreasing Claudin 5 and increasing receptor for
RAGE.60 In the present study, we found that adiponectin
suppresses the loss of tight junction proteins and the increase
of RAGE expression in brain endothelial cells under Aβ-
induced toxicity.
In the AD brain, Aβ could be transported into the brain
across the BBB and it is regulated by the BBB receptors and
transporters.61,62 Aβ accumulation in AD brain results from
decreased clearance from BBB and increase of uptake from
the circulatory system.61,62 RAGE transports Aβ from the
circulation into the brain,63,64 whereas LRP-1 is related with
rapid clearance of Aβ from the brain to blood.65–68 The
dysfunction of LRP-1 weakens the ability of BBB to clearing
Aβ.67 Several clinical studies have demonstrated that the
onset and procession of AD is associated with low LRP-1
levels and high RAGE levels, leading to the accumulation of Aβ
peptides in the brain parenchyma.69,70 One clinical study has
observed that the expression of LRP-1 is reduced and the
expression of RAGE is increased in AD patients.71 According
to the current study, 5xFAD mice have decreased levels of
LRP-1 receptor and lower levels of Aβ in plasma, with an
increase of Aβ in the brain.72 Aβ oligomers are known to cause
upregulation of RAGE expression in endothelial cells.73 This
may have important consequences given that RAGE pro-
motes the expression of MMP-2 related with permeability.74,75
One study has reported that Aβ triggers the increase of
permeability and the disruption of tight junction protein ZO-1
and the secretion of MMP in brain endothelial cells by
interacting with RAGE.15,34 In recent years, an inverse
relationship was found to exist between the expression of
adiponectin and RAGE.76,77 Given that our results showed low
mRNA level of RAGE and high mRNA level of LRP-1 in Aβ-
exposed bEnd.3 cells by Acrp 30 treatment, we assume that
adiponectin contributes to the transportation of Aβ into brain
and the clearance of Aβ by enhancing the expression of LRP-1
and suppressing the level of RAGE in brain endothelial cells.
Even though we did not find a direct mechanistic connection
between adiponectin and Aβ-RAGE or Aβ-LRP-1 interaction in
this study, we highlight the necessity of further study
concerning the action of adiponectin related with Aβ
transporters.
Moreover, previous studies demonstrated that adiponectin
negatively regulates the production of pro-inflammatory
cytokines including MCP-1, IL-6 in endothelial cells by
modulating the activation of NF-κB.78,79 Based on our results,
we assume that adiponectin may regulate the expression of
pro-inflammatory cytokines and inflammatory responses by
inhibiting the activation of NF-κB in brain endothelial cells
under Aβ toxicity. In particular, we found that AdipoR1
mediates the effect of adiponectin such as the suppression
of NF-κB phosphorylation and the protection of tight junction
protein loss.
Taken together, we assume that adiponectin may alleviate
the BBB disruption in AD (1) by inhibiting apoptosis of brain
endothelial cells, (2) by protecting tight junction integrity, and
(3) by mediating the balance of Aβ transporters in brain
endothelial cells. Furthermore, AdiopoR1may be crucial in the
inflammatory response through NF-κB and the loss of tight
junction protein in brain endothelial cells. Hence, we suggest
that the action of adiponectin through AdipoR1 may alleviate
AD pathogenesis by protecting BBB disruption.
Materials and Methods
Animal experiments. Male 5xFAD transgenic mice (strain: B6SJL-Tg
[APPSwFlLon, PS1*M146L*L286V] 6799Vas/J, 5 months) were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). 5xFAD mice were detected Aβ42
production in brain at 2 months.80 Wild-type male C57BL/6 mice (25–30 g,
5 months) were provided by Koatech (Koatech, Pyeongtaek, South Korea). Animal
treatment and maintenance were performed in accordance with the Animal Care
Guidelines of Chonnam National University, South Korea.
Cell culture and drug treatment. We used mouse brain endothelial cells
(bEnd.3 cells). bEnd.3 cells were cultured in Dulbecco modified Eagle’s medium
(Gibco, Grand Island, NY, USA) which contained 0.45% glucose, 0.37% NaHCO3,
4 mM glutamine, 10% FBS, 100 μg/ml penicillin, and 100 μg/ml streptomycin.
bEnd.3 cells were grown in a humidified incubator at 37 °C with 5% CO2. bEnd.3
cells were pretreated with Acrp 30 (10 μg/ml) (Sigma-Aldrich, St. Louis, MO, USA)
for 24 h and were subsequently treated with Aβ (1–20 μM) for 24 h.
Aβ oligomer preparation. Oligomeric Aβ were prepared following previous
report.81 Synthetic Aβ 42 peptide (American Peptide, Sunnyvale, CA, USA) was
dissolved to 1 mM hexafluoroisopropanol (Sigma-Aldrich). The solution was
evaporated for 2 h and subsequently peptide film was resuspended in dimethyl
sulfoxide (DMSO, Sigma-Aldrich) to produce a 1 mM solution. Later, to prepare
oligomeric Aβ 42, this solution was diluted to 100 μM in DMSO medium (Gibco) and
incubated for 12 h at 4 °C.
Preparation of the AdipoR1 and AdipoR2 targeting siRNA. A small
interfering RNA for AdipoR1 (5 μM) was prepared to silence AdipoR1 siRNA sc-
60123 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). A small interfering RNA
for AdipoR2 (5 μM) was prepared to silence AdipoR2 siRNA sc-46756 (Santa Cruz
Figure 8 The alteration of Claudin 5 and phosphorylated NF-κB protein’s expression by inhibiting AdipoR1. (a) The expression of Claudin 5 was assessed by
immunocytochemistry. Pre-treatment of Acrp 30 did not reverse the Aβ-induced decrease of Claudin 5 expression in bEnd.3 cells in the presence of AdipoR1 knockdown using
siRNA AdipoR1. (b) The expression of p-NF-κB was checked by immunocytochemistry. Pre-treatment of Acrp 30 did not reverse the Aβ-induced increase of p-NF-κB expression
in bEnd.3 cells in the presence of AdipoR1 knockdown using siRNA AdipoR1. (c) The expression of NF-κB was checked by immunocytochemistry in bEnd.3 cells in the presence
of AdipoR1 knockdown using siRNA AdipoR1.Acrp30: Acrp 30 10 μg/ml treatment for 24 h, Aβ: Aβ 20 μM treatment for 24 h, siAdipoR1: silencing of AdipoR1, Scale bar: 50 μm,
4',6-diamidino-2-phenylindole (DAPI): blue, Claudin 5: green, NF-kB: green, p-NF-kB: green, (− ) Ab: IgG control
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Biotechnology). For the transfection of siRNA, a 5 μM final concentration of siRNA
AdipoR1 and siAdipoR2 were mixed with lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) in Opti-MEM medium and incubated at room temperature for 15 min. The
mixture was added to bEnd.3 cells in six-well plates. After 2 days, they were
harvested for total protein or RNA extraction.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. bEnd.3 cells (2 × 105 cells/ml) were seeded in 96-well plates to
check all conditions, including Acrp30 (10 μg/ml) pre-treatment (24 h) and Aβ
(20 μM) treatment (24 h). Later, cells were rinsed twice with PBS, and culture
medium was replaced with serum-free medium. Then, 100 μl of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) solu-
tion (2 mg/ml in PBS) was added per well.82 After 90 min of incubation, medium
was removed, and DMSO was added to solubilize the purple formazan product of
the MTT reaction. The supernatant was measured using an ELISA reader at a
wavelength of 570 nm. All experiments were repeated four times. Cell viabilities are
expressed relative to non-treatment controls (considered to be 100%).82
Determination of nitrite. bEnd.3 cells were plated onto 96-well plates and
pre-treated with Acrp30 (10 μg/ml) 24 h prior to stimulation with 20 μM of Aβ.
Supernatants were collected and checked nitric oxide (NO) production using Griess
reagent. The Griess reagents (100 μl) were added to the plate and incubated for
30 min at room temperature. The absorbance of supernatants was measured at
540 nm using the ELISA reader (Versamax Molecular Devices, Hampton,
NH, USA).
ROS assay. Oxidized DCF (reflecting the levels of H2O2 and ONOO
−) in bEnd.3
cells was measured by using the DCF-DA (Sigma-Aldrich) assay as described
previously.83 Later, bEnd.3 cells were washed with PBS. Then bEnd.3 cells were
loaded with the probe DCF-DA (5 μM) and incubated for 40 min at 37 °C in PBS.
Incubated bEnd.3 cells were washed with PBS to remove the excess DCF probe.
DCF images in cells were acquired by confocal microscope (Carl Zeiss, Thornwood,
NY, USA) at an excitation of 488 nm and emission of 525 nm in cells.
Hoechst 33258 and propidium iodide (PI) staining. Cell death was
assessed by staining bEnd.3 cells with Hoechst 33258 dye (Sigma-Aldrich) and
propidium iodide (PI; Sigma-Aldrich). Hoechst dye was added to the culture medium
(10 μg/ml) and samples were then incubated at 37.5 °C for 30 min. PI solution was
then added (5 μg/ml) just before cells were observed by confocal microscope (Carl
Zeiss). PI-positive cells were counted as dead bEnd.3 cells.
ELISA assay. bEnd.3 cells were plated in six-well plates (5 × 105 cells/ml) and
incubated with Acrp30 (10 μg/ml) in the presence of Aβ 20 μM for 24 h. The
production of TNF-α was measured by Mouse TNF-α ELISA kit (eBioscience, San
Diego, CA, USA; Cat No 88-7324) following the manufacturer’s instructions. The
absorbance at 450 nm was detected using an ELISA microplate reader.
Western blot analysis. bEnd.3 cells were washed with PBS and collected.
Cell pellets were lysed with ice-cold RIPA buffer (Sigma-Aldrich). The lysates were
centrifuged at 13 000 rpm for 30 min at 4 °C to produce whole-cell extracts. Protein
(30 μg) in cells was separated on a 12% SDS-polyacrylamide gel and transferred
onto a polyvinylidene difluoride membrane. After blocking with skimmed milk
prepared in Tris-buffered saline-tween (TBST) (20 nM Tris (pH 7.2), 150 mM NaCl,
0.1% Tween 20) for 1 h at room temperature, immunoblots were incubated for 16 h
at 4 °C with primary antibodies that detect p-NF-κB (1:1000, Cell Signaling,
Danvers, MA, USA), NF-κB (1:1000, Cell Signaling), AdipoR1 (1:1000, Abcam,
Cambridge, MA, USA), AdipoR2 (1:1000, Abcam), Claudin 5 (1:1000, Cell
Signaling), CD31 (1:1000, Abcam) or β-actin (1:1000; Millipore, Billerica, MA, USA).
Blots were then incubated with each secondary antibody (Abcam) for 1 h and
30 min at room temperature. Blots were visualized by ECL solution (Millipore).
Quantitative real-time PCR. To examine the amount of Claudin 5, ZO-1,
TNF-α, IL-6, MCP-1, Bax, AdipoR1, AdipoR2, iNOS, eNOS, LRP-1, RAGE mRNA
in bEnd.3 cells, quantitative real-time PCR was performed using each primer. Total
cellular RNA was extracted from bEnd.3 cells using Trizol reagent (Invitrogen)
following manual. RNA was mixed with One Step SYBR Prime Script TM RT-PCR
Kit II (Takara, Otsu, Shiga, Japan) and specific primers in a total reaction volume of
20 μl. PCR was performed using the following primers (5′ to 3′); Claudin 5 (F):
CTG CTG GTT CGC CAA CAT T, (R): TGC GAC ACG GGC ACA G, ZO-1 (F):
CAG CCG GTC ACG ATC TCC T,(R): TCC GGA GAC TGC CAT TGC, AdipoR1
(F):CCCACCATGCACTTTACTAT, (R) CACCATAGAAGTGGACGAAA, AdipoR2 (F):
CAACCTTGCTTCATCTACCT, (R): CTAGCCATAAGCATTAGCCA, iNOS (F):
GGG AAT CTT GGA GCG AGT TG, (R): GTG AGG GCT TGG CTG AGT GA,
eNOS (F): TCCGGAAGGCGTTTGATC, (R): GCCAAATGTGCTGGTCACC; TNF-α
(F): CGT CAG CCG ATT TGC TAT CT, (R): CGG ACT CCG CAA AGT CTA AG ;
IL-6 (F): GTT GCC TTC TTG GGA CTG AT, (R): CTG GCT TTG TCT
TTC TTG TTA T ; MCP-1 (F): CCC ACT CAC CTG CTG CTA CT, (R):
TCT GGA CCC ATT CCT TCT TG ; Bax (F): AAG AAG CTG AGC GAG TGT, (R):
GGA GGA AGT CCA ATG TC, LRP-1 (F):GAG TGT TCC GTG TAT GGC AC, (R):
GAT GCC TTG GAT GAT GGT C, RAGE (F):TGG AAC CGT AAC CCT DAC CT,
(R):CGA TGA TGC TGA TGC TGA CA, GAPDH (F): GAC AAG CTT
CCC GTT CTC AG, (R): GAG TCA ACG GAT TTG GTC GT. Amplification cycles
were conducted at 52 °C for 5 min, 95 °C for 10 s, 95 °C for 5 s, 60 °C for 35 s, and
65 °C for 15 s. Quantitative SYBR Green real-time PCR was performed with Takara
PCR System (Takara) and analyzed with comparative Ct quantification. GAPDH
was used as an internal control. The ΔCt values of treated cells were compared
with those of untreated cells.84
Reverse transcription PCR. RNA in bEnd.3 cells was isolated using Trizol
Reagent (Gibco) following the manufacturer’s instructions. RT-PCR reaction was
performed by using Invitrogen One step III Reverse Transcription PCR kit
(Invitrogen). cDNA synthesis from mRNA and sample normalization were
performed. PCR was performed using the following thermal cycling conditions:
95 °C for 10 min; 40 cycles of denaturing at 95 °C for 15 s, annealing at 58 °C for
30 s, elongation at 72 °C for 30 s; final extension at 72 °C for 5 min; and holding at
4 °C. PCR was performed using the following primers (5′ to 3′); Bcl2 (F):
TACCGTCGTGACTTCGCAGAG, (R): GGCAGGCTGAGCAGGGTCTT, GAPDH
(F): GAC AAG CTT CCC GTT CTC AG, (R):
GAG TCA ACG GAT TTG GTC GT. PCR products were electrophoresed in 1%
agarose gels and stained with cyber green. Each sample was normalized
with GAPDH.
Immunocytochemistry. bEnd.3 cells were washed thrice with PBS, and
were permeabilized for 20 min. bEnd.3 cells were incubated with the primary
antibodies for 16 h at 4 °C. The following primary antibodies were used: anti-rabbit
AdipoR1 (1:500, Abcam), anti-goat AdipoR2 (1:500, Abcam), anti-rabbit NF-κB
(1:500, Cell Signaling), anti-rabbit p-NF-κB (1:500, Cell Signaling), anti-rabbit CD31
(1:500, Abcam), and anti-rabbit Claudin 5 (1:500, Cell Signaling). After 16 h
incubation, bEnd.3 cells were washed twice with PBS. bEnd.3 cells were incubated
with each specific secondary antibody for 1 h and 30 min at room temperature.
bEnd.3 cells were counterstained with 1 μg/ml 4', 6-diamidino-2-phenylindole (DAPI,
1:100, Invitrogen) for 10 min at room temperature. Images were obtained using
confocal microscope (Carl Zeiss).
Immunohistochemistry. Brain sections were cut (20 μm) onto coated glass
slides (Thermo Scientific, Waltham, MA, USA), and fixed in acetone for 20 min at
− 20 °C. The slides were first washed in TBS and then incubated with methanol. To
block nonspecific labeling, sections were incubated in 5% bovine serum albumin
(Sigma-Aldrich) diluted in PBS for 1 h before incubation with primary and secondary
antibodies. Primary antibodies for AdipoR1 (1:500, Abcam), AdipoR2 (1:500,
Abcam), postsynaptic density protein 95 (PSD95) (1:500, Cell Signaling) were
applied to the samples for 16 h at 4 °C, followed by 1 h incubation with appropriate
florescence secondary antibody (1:500, Invitrogen) and three times washes in PBS
for 5 min each. After three washes in 0.1 % PBS with Tween-20, the sections were
incubated with each secondary antibody for 1 h in the dark at room temperature.
Later, all sections were incubated with 1 μg/ml DAPI (Sigma-Aldrich) for a counter
staining. Brain tissues were then visualized under a confocal microscope (Carl
Zeiss, Oberkochen, Germany).
Statistical analysis. Statistical analysis was conducted by SPSS 18.0
software (IBM Corp., Armonk, NY, USA). Results are expressed as the
mean± standard deviations (S.D). Statistical analyses were performed using one-
way analysis of variance followed by Bonferroni post-hoc multiple comparison.
Differences were considered statistically significant at *Po0.05 and **Po0.001.
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